To test if expression of CD200 on melanoma cells could improve the susceptibility to T cell therapy, we injected 5×105 of B16.OVA.Ctrl or B16.OVA.CD200 tumor cells into each Rag−/−C57BL/6 mouse subcutaneously. This evidence concerns the gene CD200 and neoplasm.